| Trade Names: | |
| Synonyms: | |
| Status: | Approved (2007) |
| Entry Type: | Small molecule |
| Molecule Category: | UNKNOWN |
| ATC: | L01DC04 |
| UNII: | K27005NP0A |
Structure
| InChI Key | FABUFPQFXZVHFB-PVYNADRNSA-N |
|---|---|
| Smile | |
| InChI |
|
Physicochemical Descriptors
| Property Name | Value |
|---|---|
| Molecular Formula | C27H42N2O5S |
| Molecular Weight | 506.71 |
| AlogP | 4.05 |
| Hydrogen Bond Acceptor | 7.0 |
| Hydrogen Bond Donor | 3.0 |
| Number of Rotational Bond | 2.0 |
| Polar Surface Area | 112.05 |
| Molecular species | NEUTRAL |
| Aromatic Rings | 1.0 |
| Heavy Atoms | 35.0 |
Pharmacology
| Targets | EC50(nM) | IC50(nM) | Kd(nM) | Ki(nM) | Inhibition(%) | |
|---|---|---|---|---|---|---|
|
Ion channel
Other ion channel
Miscellaneous ion channel
Bcl-2 family
|
- | - | 337 | - | - |
Indications
| Mesh Heading | Maximum Phase | Mesh ID | Reference |
|---|---|---|---|
| Breast Neoplasms | 4 | D001943 | FDA |
| Breast Neoplasms | 4 | D001943 | ClinicalTrials |
| Neoplasms | 4 | D009369 | ClinicalTrials |
| Endometrial Neoplasms | 3 | D016889 | ClinicalTrials |
| Burkitt Lymphoma | 2 | D002051 | ClinicalTrials |
| Lymphoma, Large B-Cell, Diffuse | 2 | D016403 | ClinicalTrials |
| Leukemia | 2 | D007938 | ClinicalTrials |
| Lymphoma | 2 | D008223 | ClinicalTrials |
| Carcinoma, Renal Cell | 2 | D002292 | ClinicalTrials |
| Pancreatic Neoplasms | 2 | D010190 | ClinicalTrials |
| Lymphoma, Large-Cell, Anaplastic | 2 | D017728 | ClinicalTrials |
| Carcinoma, Non-Small-Cell Lung | 2 | D002289 | ClinicalTrials |
| Tongue Neoplasms | 2 | D014062 | ClinicalTrials |
| Breast Neoplasms, Male | 2 | D018567 | ClinicalTrials |
| Carcinoma, Verrucous | 2 | D018289 | ClinicalTrials |
| Lymphoma, Mantle-Cell | 2 | D020522 | ClinicalTrials |
| Colorectal Neoplasms | 2 | D015179 | ClinicalTrials |
| Hypopharyngeal Neoplasms | 2 | D007012 | ClinicalTrials |
| Retroviridae Infections | 2 | D012192 | ClinicalTrials |
| Sarcoma | 2 | D012509 | ClinicalTrials |
| Peritoneal Neoplasms | 2 | D010534 | ClinicalTrials |
| Fallopian Tube Neoplasms | 2 | D005185 | ClinicalTrials |
| Urethral Neoplasms | 2 | D014523 | ClinicalTrials |
| Squamous Cell Carcinoma of Head and Neck | 2 | D000077195 | ClinicalTrials |
| Stomach Neoplasms | 2 | D013274 | ClinicalTrials |
| Melanoma | 2 | D008545 | ClinicalTrials |
| Prostatic Neoplasms | 2 | D011471 | ClinicalTrials |
| Carcinoma, Renal Cell | 2 | D002292 | ClinicalTrials |
| Urinary Bladder Neoplasms | 2 | D001749 | ClinicalTrials |
| Lung Neoplasms | 2 | D008175 | ClinicalTrials |
| Lymphoma, Follicular | 2 | D008224 | ClinicalTrials |
| Oropharyngeal Neoplasms | 2 | D009959 | ClinicalTrials |
| Ovarian Neoplasms | 2 | D010051 | ClinicalTrials |
| Prostatic Neoplasms, Castration-Resistant | 2 | D064129 | ClinicalTrials |
| Gliosarcoma | 1 | D018316 | ClinicalTrials |
| Astrocytoma | 1 | D001254 | ClinicalTrials |
| Head and Neck Neoplasms | 1 | D006258 | ClinicalTrials |
Related Entries
MCS
Side Effects from Label
Side Effects (PT)
Adverse Reactions
System Organ Classification (SOC)
Cross References
| Resources | Reference |
|---|---|
| CAS NUMBER | 219989-84-1 |
| ChEBI | 63605 |
| ChEMBL | CHEMBL1201752 |
| DrugBank | DB04845 |
| DrugCentral | 1517 |
| EPA CompTox | DTXSID70870252 |
| FDA SRS | K27005NP0A |
| Guide to Pharmacology | 6824 |
| PDB | GZX |
| PubChem | 6445540 |
| SureChEMBL | SCHEMBL8386 |
| ZINC | ZINC000003993846 |
CONTENTS